AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $521.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
AbbVie Inc (ABBV) Stock Forecast
Analysts expect AbbVie (ABBV) to earn $13.98 per share in the fiscal year ending Dec 31, 2026, on revenue of $67.80B. Of 29 analysts, 23 rate the stock Buy or Strong Buy, 5 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $16.20.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 2.03, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 7 | 24.1% |
| Buy | 16 | 55.2% |
| Hold | 5 | 17.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 3.4% |
- Consensus
- Buy
- Total analysts
- 29
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 15.9% and revenue estimates rise 9.1%.
- Fiscal year ending Dec 31, 2026
- $13.98
- EPS consensus, revenue $67.80B
- Fiscal year ending Dec 31, 2027
- $16.20
- EPS consensus, revenue $73.94B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $13.98 | $13.93 to $14.13 | 28 | $67.80B | $67.70B to $67.98B | 25 |
| Dec 31, 2027 | $16.20 | $15.31 to $17.23 | 29 | $73.94B | $71.98B to $75.96B | 25 |
Quarterly Estimates
The EPS consensus falls from $3.95 for the quarter ending Dec 31, 2026 to $3.44 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.95 | $3.73 to $4.21 | 26 | $18.78B | $17.96B to $19.40B | 25 |
| Mar 31, 2027 | $3.44 | $3.31 to $3.90 | 9 | $16.43B | $15.89B to $17.20B | 6 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.2% from $14.01.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $13.98 | $13.99 | $13.97 | $14.01 | $14.01 | -0.2% |
| Fiscal year ending Dec 31, 2027 | $16.20 | $16.18 | $16.22 | $16.27 | $16.28 | -0.5% |
| Quarter ending Mar 31, 2027 | $3.44 | $3.33 | $3.34 | $3.34 | $3.34 | +2.8% |
Frequently Asked Questions About ABBV
What is the ABBV stock forecast?
Consensus analyst estimates put AbbVie's EPS at $13.98 for the fiscal year ending Dec 31, 2026, on revenue of $67.80B. The consensus rating from 29 analysts is Buy.
How do analysts rate ABBV stock?
Of 29 analysts covering AbbVie, 7 rate it Strong Buy, 16 Buy, 5 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ABBV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $13.98, with estimates from $13.93 to $14.13 from 28 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.20, with estimates from $15.31 to $17.23 from 29 analysts.
What revenue do analysts expect from AbbVie next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $67.80B, with estimates from $67.70B to $67.98B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $73.94B, with estimates from $71.98B to $75.96B.
How many analysts cover ABBV?
29 analysts rate AbbVie stock, and 28 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ABBV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts